BPC-157 vs Fenbendazole for dogs

BPC-157

BPC-157 has the most directly relevant safety data of any compound on this site as it applies to dogs. A dedicated preclinical toxicity evaluation covering mice, rats, rabbits and dogs reported that it was well tolerated with no serious toxicity, no genotoxicity and no embryo-fetal toxicity; the single notable finding was a decrease in creatinine at 2 mg/kg, which resolved spontaneously after two weeks of withdrawal and did not occur at lower doses. Local irritation was mild. The meaningful caveat is duration rather than dose — those studies covered single and repeated dosing, not months of continuous administration.

Fenbendazole

Fenbendazole at its labelled three-day deworming dose is one of the safest drugs in veterinary medicine, which is exactly why the extended oncology schedules get discussed so casually — and why that framing is misleading. Published canine case reports document pancytopenia and bone marrow hypoplasia during fenbendazole therapy, both resolving after the drug was withdrawn, and hepatic injury has been reported in humans self-administering it. Those reports are individual cases rather than a controlled series, so the true frequency is unknown — which is an argument for the monitoring, not against it. The three-on / four-off cycling and the monthly CBC exist specifically to manage that risk. It also must not be combined with vincristine or paclitaxel.